Anuh Pharma (BOM:506260) Cyclically Adjusted Revenue per Share: ₹56.48 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:506260 Anuh Pharma Ltd BOM:506260
86 GF Score
Price ₹83.82
GF Value ₹105.01
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Anuh Pharma Cyclically Adjusted Revenue per Share?

Anuh Pharma BOM:506260 +0.30% 86 Cyclically Adjusted Revenue per Share is ₹56.48 as of Jun. 2026. GuruFocus rates BOM:506260 with a GF Score™ of 86/100 and a GF Value™ of ₹105.01 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Anuh Pharma's adjusted revenue per share for the three months ended in Jun. 2026 was ₹19.339. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹56.48 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Anuh Pharma's average Cyclically Adjusted Revenue Growth Rate was 10.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Anuh Pharma was 8.60% per year. The lowest was 8.20% per year. And the median was 8.50% per year.

As of today (2026-08-31), Anuh Pharma's current stock price is ₹83.82. Anuh Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹56.48. Anuh Pharma's Cyclically Adjusted PS Ratio of today is 1.48.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Anuh Pharma was 2.75. The lowest was 0.93. And the median was 1.53.


Anuh Pharma  (BOM:506260) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Anuh Pharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=83.82/56.48
=1.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Anuh Pharma was 2.75. The lowest was 0.93. And the median was 1.53.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Anuh Pharma Cyclically Adjusted Revenue per Share Related Terms


Anuh Pharma Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Anuh Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anuh Pharma Cyclically Adjusted Revenue per Share Chart

Anuh Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.36 42.67 46.48 49.81 54.46

Anuh Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.99 52.20 53.24 54.46 56.48

BOM:506260 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Anuh Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anuh Pharma Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anuh Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Anuh Pharma's Cyclically Adjusted PS Ratio falls into.


BOM:506260
86GF Score
Anuh Pharma Ltd BOM:506260
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anuh Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Anuh Pharma's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=19.339/167.3573*167.3573
=19.339

Current CPI (Jun. 2026) = 167.3573.

Anuh Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 4.837 105.961 7.640
201612 5.316 105.196 8.457
201703 5.445 105.196 8.663
201706 5.175 107.109 8.086
201709 5.485 109.021 8.420
201712 6.321 109.404 9.669
201803 6.699 109.786 10.212
201806 7.994 111.317 12.018
201809 8.729 115.142 12.687
201812 6.969 115.142 10.129
201903 8.302 118.202 11.754
201906 8.455 120.880 11.706
201909 7.392 123.175 10.043
201912 7.595 126.235 10.069
202003 7.177 124.705 9.632
202006 12.409 127.000 16.352
202009 11.159 130.118 14.353
202012 9.762 130.889 12.482
202103 9.670 131.771 12.282
202106 11.747 134.084 14.662
202109 10.877 135.847 13.400
202112 13.170 138.161 15.953
202203 12.846 138.822 15.487
202206 11.582 142.347 13.617
202209 11.489 144.661 13.292
202212 13.864 145.763 15.918
202303 15.691 146.865 17.880
202306 16.144 150.280 17.979
202309 14.917 151.492 16.479
202312 17.153 152.924 18.772
202403 16.352 153.035 17.882
202406 13.778 155.789 14.801
202409 16.548 157.882 17.541
202412 15.885 158.323 16.791
202503 19.723 157.552 20.951
202506 18.606 159.755 19.491
202509 18.558 162.289 19.138
202512 19.643 163.281 20.133
202603 20.244 164.272 20.624
202606 19.339 167.357 19.339

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹56.48 mean?
Anuh Pharma (BOM:506260) has a Cyclically Adjusted Revenue per Share of ₹56.48 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Anuh Pharma and its competitors.
Is Anuh Pharma's Cyclically Adjusted Revenue per Share too high?
Anuh Pharma's current Cyclically Adjusted Revenue per Share is ₹56.48. Overall, Anuh Pharma has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anuh Pharma's Cyclically Adjusted Revenue per Share compare to ZTS?
Anuh Pharma's Cyclically Adjusted Revenue per Share of ₹56.48 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Anuh Pharma and its competitors. Anuh Pharma's current Cyclically Adjusted Revenue per Share is ₹56.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anuh Pharma stock overvalued right now?
Based on GuruFocus' analysis, Anuh Pharma (BOM:506260) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹105.01, compared to a current price of ₹83.82 — trading 20.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹56.48. Anuh Pharma's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Anuh Pharma (BOM:506260), the current Cyclically Adjusted Revenue per Share is ₹56.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anuh Pharma (BOM:506260) Overvalued in 2026?

Based on GuruFocus' analysis, Anuh Pharma stock appears to be undervalued. The current stock price of ₹83.82 is trading 20.2% below its estimated GF Value™ of ₹105.01. GuruFocus considers Anuh Pharma to be Modestly Undervalued.

Key valuation signals for BOM:506260:

  • Cyclically Adjusted Revenue per Share: ₹56.48
  • GF Value™: ₹105.01 vs. price of ₹83.82 (20.2% below fair value)
  • GF Score™: 86/100 with 2 warning signs

No single metric tells the full story. See the BOM:506260 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Anuh Pharma Business Description

Other Exchanges ANUHPHR:India
Address Dr. Annie Besant Road, North Wing, 3-A, Shiv Sagar Estate, Worli, Mumbai, MH, IND, 400 018
Anuh Pharma Ltd is engaged in the business of manufacturing and selling of Bulk drugs and chemicals. Geographically, it derives a majority of revenue from India. Its product categories include macrolides, anti-TB, anti-malarial, anti-bacterial, anti-hypertension, expectorant, quinolones, and others. The company generates revenue from the sale of Branded Prescription drugs, Over-the-Counter (OTC) drugs and Generic Prescription drugs.
86GF Score

Get the complete analysis for BOM:506260

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹83.82
Price
₹105.01
GF Value